Maravai LifeSciences Holdings Inc. Class A Common Stock vs PulteGroup, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while PulteGroup, Inc. trades at $110.09 (market cap $21.25B). The key difference: PulteGroup, Inc. is far larger — about 21.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and PulteGroup, Inc. pays a 0.93% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and PulteGroup, Inc. for 91 Days on average.
| MRVI | PHM | |
|---|---|---|
Market Cap | $972.90M | $21.25B |
Volume | 4,325,710 | 1,784,813 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $142.56 |
52-Week Low | $2.83 | $109.35 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $1.08B | $21.67B |
Dividend Yield | — | 0.93% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
PulteGroup (PHM) trades at $109.35, down 1.61% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though it beat expectations in Q2 2026. Fundamentally, the company maintains solid profitability with 11.62% net margin and attractive valuation at 11.4 P/E. Analyst consensus remains mixed with 45% buy ratings but a $139.64 price target suggesting 28% upside potential from current levels.
PHM presents a value opportunity with strong cash flow generation and dividend yield, though near-term headwinds from rising interest rates and housing affordability concerns create volatility. The stock's current discount to analyst targets and reasonable valuation metrics support long-term potential, but investors should monitor Q3 2026 earnings on October 22 for confirmation of business resilience.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →